Physician profile
David W Jahn
NPI 1508802224
$519,219.80
in general payments reported to CMS, 2019-2025
32 companies · $125K in 2025
The $125K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $11K · 2021: $47K · 2022: $91K · 2023: $83K · 2024: $110K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $242K · Travel and Lodging: $22K · Consulting Fee: $21K · Food and Beverage: $18K · Honoraria: $15K · Education: $44.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $241,930.00 |
| Travel and Lodging | $21,788.39 |
| Consulting Fee | $20,700.00 |
| Food and Beverage | $18,448.70 |
| Honoraria | $14,982.50 |
| Education | $44.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170,731.01 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $122,212.78 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $85,140.93 | 2021-2025 | |
| Alkermes, INC. | $69,007.31 | 2019-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $32,934.60 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $20,456.16 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $10,563.89 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $1,964.20 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,270.28 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,199.63 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $580.73 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $472.03 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $374.15 | 2019-2025 | Trintellix |
| Indivior INC. | $354.43 | 2019-2024 | Perseris, Sublocade |
| Sunovion Pharmaceuticals INC. | $307.74 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $282.58 | 2023-2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $217.53 | 2021-2022 | |
| Bausch Health US, LLC | $212.43 | 2022-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $192.68 | 2022-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $172.85 | 2023-2024 | Jornay Pm |
| Almatica Pharma LLC | $104.26 | 2023 | Loreev Xr, Sertraline Hcl |
| Jazz Pharmaceuticals INC. | $92.77 | 2022 | |
| Idorsia Pharmaceuticals US INC | $76.07 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $61.35 | 2022-2023 | Xelstrym, Secuado |
| Luye Pharma (USA) Ltd. | $48.33 | 2025 | Erzofri Extended-Release |
| Tris Pharma INC | $34.29 | 2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $34.24 | 2019-2020 | |
| Eisai INC. | $31.10 | 2021 | |
| Neos Therapeutics, Lp | $26.81 | 2022-2024 | Adzenys Xr-Odt |
| Harmony Biosciences LLC | $23.89 | 2024 | |
| Sage Therapeutics, LLC | $20.50 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $18.25 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.